News
Thermo Fisher Scientific Extends Collaboration with Biognosys to Enhance Protein Quantitation Mass Spectrometry Workflows
Thermo Fisher Scientific, the world leader in serving science, and Biognosys, a leading developer of next-generation proteomics solutions, announce they are continuing their collaboration to advance data independent acquisition (DIA) mass spectrometry-based workflows. Together, the companies have developed a...
News
Merck to acquire Themis for SARS-CoV-2 vaccine
Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2.
Themis has a pipeline of vaccine candidates and immune modulatory therapies developed using its...
Drug Research
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in...
Clinical Trials
Glenmark to Combine Two Anti-Viral Drugs; Start Trials on Indian COVID-19 Patients
Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India. Glenmark has received approval from the...
Clinical Trials
AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC).
ArcherDX’s personalised assay will be used in...
News
Demand for immunity products to be sustained long-term say SIRIO
SIRIO Europe (Ayanda) – the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO) – says considerable worldwide demand for immunity products has accelerated in recent months due coronavirus, but it is...
Clinical Trials
US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India
US pharmaceutical giant Gilead Sciences is likely to apply to India's Central Drugs Standard Control Organisation (CDSCO) soon seeking marketing authorisation for its anti-viral drug remdesivir, which is being considered by many as a potential medication for COVID-19.
Officials of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read